血清HBV RNA的基础与临床应用研究进展

摘要/Abstract

摘要： 乙型肝炎病毒(HBV)慢性感染难以被彻底清除,其根源在于感染后形成的共价闭合环状DNA(cccDNA)微染色体可长期稳定存在于肝细胞核内。HBV RNA作为cccDNA的直接下游转录产物,近年被发现可作为一种新型无创指标用于监测患者肝内cccDNA的数目和转录活性,并与疾病预后密切相关。本文综述了当前血清HBV RNA的基础与临床应用研究进展,并展望了未来有关HBV RNA的研究方向,期望推进其在慢性肝病领域的临床转化。

关键词: 乙型肝炎病毒, HBV RNA, 分子特征, 临床应用

方芷欣, 邓芮, 孙剑. 血清HBV RNA的基础与临床应用研究进展[J]. 肝脏, 2023, 28(1): 30-32.

参考文献

[1] Organization WH. Interim guidance for country validation of viral hepatitis elimination. 2021.
[2] Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res,2020,180:104824.
[3] Cornberg M, Lok AS, Terrault NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger). J Hepatol,2020,72:539-557.
[4] Liu YY, Liang XS. Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA. World J Hepatol,2018,10:603-611.
[5] Liu S, Zhou B, Valdes JD, et al. Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology,2019,69:1816-1827.
[6] Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol, 2016,65:700-710.
[7] Stadelmayer B, Diederichs A, Chapus F, et al. Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. J Hepatol,2020,73:40-51.
[8] Shen S, Xie Z, Cai D, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA. PLoS Pathog,2020,16:e1008945.
[9] Bai L, Zhang X, Kozlowski M, et al. Extracellular Hepatitis B Virus RNAs Are Heterogeneous in Length and Circulate as Capsid-Antibody Complexes in Addition to Virions in Chronic Hepatitis B Patients. J Virol,2018,92.
[10] Liu Y, Liu H, Hu Z, et al. Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. Hepatology,2020,71:463-476.
[11] K?ck J, Theilmann L, Galle P, et al. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology, 1996,23:405-413.
[12] Mak LY, Cloherty G, Wong DK, et al. HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy. Hepatology,2021, 73(6):2167-2179.
[13] van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology,2015,61:66-76.
[14] Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. Clin Infect Dis,2021,72:202-211.
[15] Zhang M, Li G, Shang J, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int,2020,14:212-224.
[16] Fan R, Zhou B, Xu M, et al. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clin Gastroenterol Hepatol,2020,18:719-727.e7.
[17] Fan R, Peng J, Xie Q, et al. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B. J Infect Dis, 2020,222:611-618.
[18] Xia M, Chi H, Wu Y, et al. Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment. Aliment Pharmacol Ther,2021,54:709-714.
[19] Garcia-Lopez M, Lens S, Pallett LJ, et al. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. J Hepatol,2021,74:1064-1074.
[20] Lim S, Phyo W, Ling J, et al. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg). 2021;53:172-182.
[21] Mak LY, Huang Q, Wong DK, et al. Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. J Gastroenterol,2021,56:479-488.
[22] Liu S, Deng R, Zhou B, et al. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy. J Infect Dis,2022,226:881-890.